On behalf of TYG, Dr. Paul Broome presented the TYG100 technology at the annual AACR meeting. Historically clinically relevant titres of gastrin neutralising antibodies obtained in earlier Phase 3 trials were exceeded >100 fold with TYG100 with no serious adverse events.